多発性骨髄腫市場- 世界の規模、シェア、動向分析、機会、予測レポート、2019-2029年

世界の多発性骨髄腫市場規模は安定したCAGR 5.39%で成長し、2029年までに294億米ドルに達します。

世界の多発性骨髄腫市場は、世界的に増加する多発性骨髄腫の治療と管理への関心の高まりと、標的薬剤の急速な進歩により、活況を呈しています。

戦略コンサルティングおよび市場調査の大手企業であるBlueWeave Consulting社は、その最近の調査において、2022年の多発性骨髄腫の世界市場規模を214億6,000万米ドルと推定しました。2023年から2029年までの予測期間において、世界の多発性骨髄腫市場規模はCAGR 5.39%の著しい成長を遂げ、2029年には294億米ドルに達するとBlueWeave社は予測しています。世界の多発性骨髄腫市場の主な成長促進要因には、マイクロRNA療法の採用拡大が含まれます。これらの革新的な治療法は、遺伝子発現を制御し、多様な細胞プロセスを監督するマイクロRNAの可能性を利用しています。精密に標的化されたマイクロRNA治療法の進化は、多発性骨髄腫に対してより個別化された正確な治療法を提供することが期待されています。さらに、先進的な生物医学プラットフォームの台頭は、多発性骨髄腫市場の拡大を推進する上で極めて重要な役割を担っています。これらの多面的なプラットフォームは、疾患の分子基盤の理解、新規治療標的の同定、より効果的な治療アプローチの開発を促進する幅広い技術や方法論を包含しています。これらの洗練されたプラットフォームの能力を活用することで、研究者やヘルスケア専門家は多発性骨髄腫の複雑性をより深く掘り下げることができ、画期的な治療介入の創出を進めることができます。しかし、高い治療費と厳しい規制要件が、予測期間中の市場全体の成長を抑制すると予想されます。

本レポートの詳細な分析により、世界の多発性骨髄腫市場の成長可能性、今後の動向、統計に関する情報を提供します。また、総市場規模の予測を促進する要因も明らかにしています。本レポートは、世界の多発性骨髄腫市場における最近の技術動向や、意思決定者が健全な戦略的意思決定を行うための業界洞察を提供することをお約束します。さらに、市場の成長促進要因・課題・競争力についても分析しています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界の多発性骨髄腫市場に関する洞察

• 業界のバリューチェーン分析
• DROC分析
  • 成長促進要因
    • 世界中で多発性骨髄腫の発生率が増加
    • 分子標的薬の進歩
  • 抑制要因
    • 高額な治療費
    • 厳しい規制要件
  • 機会
    • 新興市場
    • 個別化医療
  • 課題
    • 競合
    • 薬剤耐性
• 技術の進歩/最近の開発
• 規制の枠組み
• ポーターのファイブフォース分析

第4章 世界の多発性骨髄腫市場概要

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • タイプ別
    • くすぶっている（緩徐進行性）多発性骨髄腫
    • 活動性（症候性）多発性骨髄腫
  • 治療別
    • 化学療法
    • 標的療法
    • 免疫調節薬
    • ステロイド
    • 骨を変える薬
    • 免疫療法
    • 骨髄/幹細胞移植
    • 放射線治療
    • 手術
    • その他
  • 診断別
    • 血液検査と尿検査
    • X線
    • 磁気共鳴画像法（MRI）
    • コンピュータ断層撮影（CTまたはCAT）スキャン
    • 陽電子放射断層撮影法（PET）またはPET-CTスキャン
    • 骨髄穿刺と生検
    • 脂肪体吸引
    • 腫瘍のバイオマーカー検査
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋（APAC）
    • ラテンアメリカ（LATAM）
    • 中東およびアフリカ（MEA）

第5章 北米多発性骨髄腫市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 治療別
  • 診断別
  • 国別
    • 米国
    • カナダ

第6章 欧州多発性骨髄腫市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 治療別
  • 診断別
  • 国別
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • ベルギー
    • ロシア
    • オランダ
    • その他欧州

第7章 アジア太平洋の多発性骨髄腫市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 治療別
  • 診断別
  • 国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリアとニュージーランド
    • インドネシア
    • マレーシア
    • シンガポール
    • ベトナム
    • APACのその他諸国

第8章 ラテンアメリカの多発性骨髄腫市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 治療別
  • 診断別
  • 国別
    • ブラジル
    • メキシコ
    • アルゼンチン
    • ペルー
    • 中南米の残りの地域

第9章 中東およびアフリカの多発性骨髄腫市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 治療別
  • 診断別
  • 国別
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • クウェート
    • 南アフリカ
    • ナイジェリア
    • アルジェリア
    • MEAの残りの部分

第10章 競合情勢

• 主要企業とその製品のリスト
• 多発性骨髄腫の世界市場シェア分析、2022年
• 経営パラメータによる競合ベンチマーキング
• 主要な戦略的展開（合併、買収、パートナーシップなど）

第11章 世界の多発性骨髄腫市場に対するCOVID-19の影響

12：企業プロファイル（会社概要、財務マトリックス、競合情勢、主要人材、主要競合、連絡先住所、戦略的展望、 SWOT分析）

• Sanofi
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck &Co., Inc.
• AstraZeneca
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd
• ONO Pharmaceutical Co., Ltd
• Takeda Pharmaceutical Company Ltd
• Roche Group
• その他の主要企業

第13章 主要な戦略的推奨事項

第14章 調査手法

Global Multiple Myeloma Market Size Grows at Steady CAGR of 5.39% to Reach USD 29.4 Billion by 2029.

Global multiple myeloma market is flourishing because of the growing focus on the treatment and management of increasing incidences of multiple myeloma globally and rapid advancements in targeted drugs.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global multiple myeloma market size at USD 21.46 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global multiple myeloma market size to grow at a significant CAGR of 5.39% reaching a value of USD 29.4 billion by 2029. Major growth drivers for the global multiple myeloma market include the increasing adoption of microRNA therapies. These innovative treatment modalities harness the potential of microRNAs to regulate gene expression and oversee diverse cellular processes. The evolution of precisely targeted microRNA therapies holds promise for delivering more individualized and accurate treatments for multiple myeloma. Furthermore, the ascent of advanced biomedicine platforms plays a pivotal role in propelling the expansion of the multiple myeloma market. These multifaceted platforms encompass a wide spectrum of technologies and methodologies that facilitate the understanding of the molecular foundations of the disease, the identification of novel therapeutic targets, and the development of more effective treatment approaches. By harnessing the capabilities of these sophisticated platforms, researchers and healthcare professionals can delve deeper into the intricacies of multiple myeloma, thereby advancing the creation of groundbreaking therapeutic interventions. However, high treatment costs and stringent regulatory requirements are anticipated to restrain the overall market growth during the forecast period.

Global Multiple Myeloma Market - Overview:

The global multiple myeloma market refers to the collective economic and commercial landscape associated with the diagnosis, treatment, and management of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The market encompasses various pharmaceutical products, medical devices, diagnostic tools, research initiatives, and healthcare services related to multiple myeloma. It involves the production, distribution, and consumption of drugs, therapies, and technologies aimed at preventing, controlling, or curing multiple myeloma, as well as efforts to enhance patient care, improve outcomes, and advance scientific understanding of the disease. The global multiple myeloma market is influenced by medical advancements, regulatory policies, research and development activities, and the demand for innovative treatment approaches in the global healthcare industry.

Impact of COVID-19 on Global Multiple Myeloma Market

COVID-19 pandemic adversely affected the global multiple myeloma market. The crisis disrupted supply chains, delayed clinical trials, and redirected healthcare resources toward managing the pandemic. Multiple myeloma patients faced challenges in accessing treatments and medical care due to overwhelmed healthcare systems and safety concerns. Telemedicine gained prominence for consultations, but in-person treatments and clinical assessments were often delayed. Additionally, financial strains on healthcare systems affected research funding and hindered the development of new therapies. Despite these setbacks, the pandemic accelerated digital health adoption and emphasized the importance of resilient healthcare systems. The Global Multiple Myeloma Market is adapting to these challenges, but its growth trajectory was undoubtedly impacted by the pandemic.

Global Multiple Myeloma Market - By Treatment

Based on treatment, the global multiple myeloma market is divided into Chemotherapy, Targeted Therapy, Immunomodulatory Drugs, Steroids, Bone-modifying Drugs, Immunotherapy, Bone Marrow/Stem Cell Transplantation, Radiation Therapy, and Surgery segments. The immunomodulatory drugs segment holds the highest share in the global multiple myeloma market by treatment. The prominence of immunomodulators in the market is attributed to various factors, including the increasing prevalence of multiple myeloma and the rising demand for these drugs. Immunomodulators play a crucial role in modifying or delaying the progression of autoimmune, inflammatory, and cancerous conditions, with notable drugs, such as Thalomid, Revlimid, and pomalyst, being used for multiple myeloma treatment. The growing incidence of multiple myeloma is a primary driver, with lenalidomide, an immunomodulatory drug, demonstrating improved outcomes in studies, enhancing progression-free survival, response depth, and overall survival rates. This is expected to boost its adoption among patients and stimulate market growth. Also, increased research and development efforts and a rising number of drug approvals further contribute to market expansion.

Competitive Landscape:

Major players operating in the global multiple myeloma market include: Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd, ONO Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Ltd, and Roche Group. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Multiple Myeloma Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Multiple Myeloma Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Multiple Myeloma Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. The rising incidence of Multiple Myeloma globally
    • 3.2.1.2. Advancements in targeted drugs
  • 3.2.2. Restraints
    • 3.2.2.1. High treatment costs
    • 3.2.2.2. Stringent regulatory requirements
  • 3.2.3. Opportunities
    • 3.2.3.1. Emerging markets
    • 3.2.3.2. Personalized medicine
  • 3.2.4. Challenges
    • 3.2.4.1. Competition
    • 3.2.4.2. Drug resistance
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Multiple Myeloma Market Overview

• 4.1. Market Size & Forecast, 2019-2029
  • 4.1.1. By Value (USD Billion)
• 4.2. Market Share and Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Smoldering (indolent) Multiple Myeloma
    • 4.2.1.2. Active (symptomatic) Multiple Myeloma
  • 4.2.2. By Treatment
    • 4.2.2.1. Chemotherapy
    • 4.2.2.2. Targeted Therapy
    • 4.2.2.3. Immunomodulatory Drugs
    • 4.2.2.4. Steroids
    • 4.2.2.5. Bone-modifying Drugs
    • 4.2.2.6. Immunotherapy
    • 4.2.2.7. Bone Marrow/Stem Cell Transplantation
    • 4.2.2.8. Radiation Therapy
    • 4.2.2.9. Surgery
    • 4.2.2.10. Others
  • 4.2.3. By Diagnosis
    • 4.2.3.1. Blood & Urine Tests
    • 4.2.3.2. X-ray
    • 4.2.3.3. Magnetic Resonance Imaging (MRI)
    • 4.2.3.4. Computed Tomography (CT or CAT) Scan
    • 4.2.3.5. Positron Emission Tomography (PET) or PET-CT Scan
    • 4.2.3.6. Bone Marrow Aspiration and Biopsy
    • 4.2.3.7. Fat Pad Aspirate
    • 4.2.3.8. Biomarker Testing of the Tumor
    • 4.2.3.9. Others
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia Pacific (APAC)
    • 4.2.4.4. Latin America (LATAM)
    • 4.2.4.5. Middle East and Africa (MEA)

5. North America Multiple Myeloma Market

• 5.1. Market Size & Forecast, 2019-2029
  • 5.1.1. By Value (USD Billion)
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Treatment
  • 5.2.3. By Diagnosis
  • 5.2.4. By Country
    • 5.2.4.1. United States
    • 5.2.4.1.1. By Type
    • 5.2.4.1.2. By Treatment
    • 5.2.4.1.3. By Diagnosis
    • 5.2.4.2. Canada
    • 5.2.4.2.1. By Type
    • 5.2.4.2.2. By Treatment
    • 5.2.4.2.3. By Diagnosis

6. Europe Multiple Myeloma Market

• 6.1. Market Size & Forecast, 2019-2029
  • 6.1.1. By Value (USD Billion)
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Diagnosis
  • 6.2.4. By Country
    • 6.2.4.1. Germany
    • 6.2.4.1.1. By Type
    • 6.2.4.1.2. By Treatment
    • 6.2.4.1.3. By Diagnosis
    • 6.2.4.2. United Kingdom
    • 6.2.4.2.1. By Type
    • 6.2.4.2.2. By Treatment
    • 6.2.4.2.3. By Diagnosis
    • 6.2.4.3. Italy
    • 6.2.4.3.1. By Type
    • 6.2.4.3.2. By Treatment
    • 6.2.4.3.3. By Diagnosis
    • 6.2.4.4. France
    • 6.2.4.4.1. By Type
    • 6.2.4.4.2. By Treatment
    • 6.2.4.4.3. By Diagnosis
    • 6.2.4.5. Spain
    • 6.2.4.5.1. By Type
    • 6.2.4.5.2. By Treatment
    • 6.2.4.5.3. By Diagnosis
    • 6.2.4.6. Belgium
    • 6.2.4.6.1. By Type
    • 6.2.4.6.2. By Treatment
    • 6.2.4.6.3. By Diagnosis
    • 6.2.4.7. Russia
    • 6.2.4.7.1. By Type
    • 6.2.4.7.2. By Treatment
    • 6.2.4.7.3. By Diagnosis
    • 6.2.4.8. The Netherlands
    • 6.2.4.8.1. By Type
    • 6.2.4.8.2. By Treatment
    • 6.2.4.8.3. By Diagnosis
    • 6.2.4.9. Rest of Europe
    • 6.2.4.9.1. By Type
    • 6.2.4.9.2. By Treatment
    • 6.2.4.9.3. By Diagnosis

7. Asia-Pacific Multiple Myeloma Market

• 7.1. Market Size & Forecast, 2019-2029
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Diagnosis
  • 7.2.4. By Country
    • 7.2.4.1. China
    • 7.2.4.1.1. By Type
    • 7.2.4.1.2. By Treatment
    • 7.2.4.1.3. By Diagnosis
    • 7.2.4.2. India
    • 7.2.4.2.1. By Type
    • 7.2.4.2.2. By Treatment
    • 7.2.4.2.3. By Diagnosis
    • 7.2.4.3. Japan
    • 7.2.4.3.1. By Type
    • 7.2.4.3.2. By Treatment
    • 7.2.4.3.3. By Diagnosis
    • 7.2.4.4. South Korea
    • 7.2.4.4.1. By Type
    • 7.2.4.4.2. By Treatment
    • 7.2.4.4.3. By Diagnosis
    • 7.2.4.5. Australia & New Zealand
    • 7.2.4.5.1. By Type
    • 7.2.4.5.2. By Treatment
    • 7.2.4.5.3. By Diagnosis
    • 7.2.4.6. Indonesia
    • 7.2.4.6.1. By Type
    • 7.2.4.6.2. By Treatment
    • 7.2.4.6.3. By Diagnosis
    • 7.2.4.7. Malaysia
    • 7.2.4.7.1. By Type
    • 7.2.4.7.2. By Treatment
    • 7.2.4.7.3. By Diagnosis
    • 7.2.4.8. Singapore
    • 7.2.4.8.1. By Type
    • 7.2.4.8.2. By Treatment
    • 7.2.4.8.3. By Diagnosis
    • 7.2.4.9. Vietnam
    • 7.2.4.9.1. By Type
    • 7.2.4.9.2. By Treatment
    • 7.2.4.9.3. By Diagnosis
    • 7.2.4.10. Rest of APAC
    • 7.2.4.10.1. By Type
    • 7.2.4.10.2. By Treatment
    • 7.2.4.10.3. By Diagnosis

8. Latin America Multiple Myeloma Market

• 8.1. Market Size & Forecast, 2019-2029
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Diagnosis
  • 8.2.4. By Country
    • 8.2.4.1. Brazil
    • 8.2.4.1.1. By Type
    • 8.2.4.1.2. By Treatment
    • 8.2.4.1.3. By Diagnosis
    • 8.2.4.2. Mexico
    • 8.2.4.2.1. By Type
    • 8.2.4.2.2. By Treatment
    • 8.2.4.2.3. By Diagnosis
    • 8.2.4.3. Argentina
    • 8.2.4.3.1. By Type
    • 8.2.4.3.2. By Treatment
    • 8.2.4.3.3. By Diagnosis
    • 8.2.4.4. Peru
    • 8.2.4.4.1. By Type
    • 8.2.4.4.2. By Treatment
    • 8.2.4.4.3. By Diagnosis
    • 8.2.4.5. Rest of LATAM
    • 8.2.4.5.1. By Type
    • 8.2.4.5.2. By Treatment
    • 8.2.4.5.3. By Diagnosis

9. Middle East & Africa Multiple Myeloma Market

• 9.1. Market Size & Forecast, 2019-2029
  • 9.1.1. By Value (USD Billion)
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Diagnosis
  • 9.2.4. By Country
    • 9.2.4.1. Saudi Arabia
    • 9.2.4.1.1. By Type
    • 9.2.4.1.2. By Treatment
    • 9.2.4.1.3. By Diagnosis
    • 9.2.4.2. UAE
    • 9.2.4.2.1. By Type
    • 9.2.4.2.2. By Treatment
    • 9.2.4.2.3. By Diagnosis
    • 9.2.4.3. Qatar
    • 9.2.4.3.1. By Type
    • 9.2.4.3.2. By Treatment
    • 9.2.4.3.3. By Diagnosis
    • 9.2.4.4. Kuwait
    • 9.2.4.4.1. By Type
    • 9.2.4.4.2. By Treatment
    • 9.2.4.4.3. By Diagnosis
    • 9.2.4.5. South Africa
    • 9.2.4.5.1. By Type
    • 9.2.4.5.2. By Treatment
    • 9.2.4.5.3. By Diagnosis
    • 9.2.4.6. Nigeria
    • 9.2.4.6.1. By Type
    • 9.2.4.6.2. By Treatment
    • 9.2.4.6.3. By Diagnosis
    • 9.2.4.7. Algeria
    • 9.2.4.7.1. By Type
    • 9.2.4.7.2. By Treatment
    • 9.2.4.7.3. By Diagnosis
    • 9.2.4.8. Rest of MEA
    • 9.2.4.8.1. By Type
    • 9.2.4.8.2. By Treatment
    • 9.2.4.8.3. By Diagnosis

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Multiple Myeloma Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Multiple Myeloma Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 12.1. Sanofi
• 12.2. Pfizer Inc.
• 12.3. GlaxoSmithKline plc
• 12.4. Novartis AG
• 12.5. Bayer AG
• 12.6. Eli Lilly and Company
• 12.7. Merck & Co., Inc.
• 12.8. AstraZeneca
• 12.9. Bristol-Myers Squibb Company
• 12.10. AbbVie Inc.
• 12.11. Teva Pharmaceutical Industries Ltd
• 12.12. ONO Pharmaceutical Co., Ltd
• 12.13. Takeda Pharmaceutical Company Ltd
• 12.14. Roche Group
• 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumptions & Limitations